Lung Fung Group Holdings (HKSE:02290) EBIT: HK$369 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02290 Lung Fung Group Holdings Ltd HKSE:02290
17 GF Score
Price HK$3.69
! 5 Warning Signs
View Full Analysis

What is Lung Fung Group Holdings EBIT?

Lung Fung Group Holdings HKSE:02290 -1.86% 17 EBIT is HK$369 Mil as of Mar. 2026. GuruFocus rates HKSE:02290 with a GF Score™ of 17/100. The stock has 5 warning signs investors should review.

Lung Fung Group Holdings's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was HK$369 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was HK$369 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lung Fung Group Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was 18.56%. Lung Fung Group Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 61.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Lung Fung Group Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 13.48%.

Lung Fung Group Holdings  (HKSE:02290) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lung Fung Group Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=367.009 * ( 1 - 17.65% )/( (1773.605 + 1482.361)/ 2 )
=302.2319115/1627.983
=18.56 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1288.971 - 159.028 - ( 61.182 - max(0, 1080.259 - 436.597+61.182))
=1773.605

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1254.481 - 185.341 - ( 73.641 - max(0, 977.854 - 564.633+73.641))
=1482.361

Note: The Operating Income data used here is one times the annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Lung Fung Group Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=368.596/( ( (334.45 + max(170.427, 0)) + (474.396 + max(215.499, 0)) )/ 2 )
=368.596/( ( 504.877 + 689.895 )/ 2 )
=368.596/597.386
=61.70 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(8.193 + 336.038 + 14.849) - (159.028 + 0 + 29.625)
=170.427

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.47 + 421.907 + 21.005) - (185.341 + 0 + 52.542)
=215.499

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lung Fung Group Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=368.596/2735.343
=13.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lung Fung Group Holdings EBIT Related Terms

Lung Fung Group Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Lung Fung Group Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lung Fung Group Holdings EBIT Chart

Lung Fung Group Holdings Annual Data
Trend Mar23 Mar24 Mar25 Mar26
EBIT
7.30 233.57 269.57 368.60

Lung Fung Group Holdings Semi-Annual Data
Mar23 Mar24 Mar25 Mar26
EBIT 7.30 233.57 269.57 368.60

HKSE:02290 vs DDS: EBIT Comparison

For the Department Stores subindustry, Lung Fung Group Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lung Fung Group Holdings EV-to-EBIT vs Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Lung Fung Group Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lung Fung Group Holdings's EV-to-EBIT falls into.


HKSE:02290
17GF Score
Lung Fung Group Holdings Ltd HKSE:02290
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lung Fung Group Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was HK$369 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$369 Mil mean?
Lung Fung Group Holdings (HKSE:02290) has a EBIT of HK$369 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lung Fung Group Holdings.
Is Lung Fung Group Holdings' EBIT too high?
Lung Fung Group Holdings' current EBIT is HK$369 Mil. Overall, Lung Fung Group Holdings has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Lung Fung Group Holdings' EBIT compare to DDS?
Lung Fung Group Holdings' EBIT of HK$369 Mil can be compared against companies in the Retail - Cyclical industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Retail - Cyclical company?
A good EBIT depends on the Retail - Cyclical industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lung Fung Group Holdings. Lung Fung Group Holdings's current EBIT is HK$369 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lung Fung Group Holdings stock overvalued right now?
Lung Fung Group Holdings (HKSE:02290) has a current EBIT of HK$369 Mil. The current EBIT is HK$369 Mil. Lung Fung Group Holdings' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Lung Fung Group Holdings (HKSE:02290), the current EBIT is HK$369 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lung Fung Group Holdings Business Description

Address 23 Yip Cheong Street, 5th Floor, Lung Fung Group Centre, Fanling, New Territories, Hong Kong, HKG
Lung Fung Group Holdings Ltd is an investment holding company. Along with its subsidiaries, the company operates as a Hong Kong-based chain retail store of beauty, health and pharmaceutical products under the 'Lung Fung' brand. It principally engaged in the sales of a wide variety of beauty products, health products, pharmaceutical products and other consumer goods such as household and daily essentials and food products. The majority of revenue is derived from the sales of Beauty products through retail stores located in Hong Kong.
17GF Score

Get the complete analysis for HKSE:02290

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.69
Price